☰
Kadmon, a clinical-stage biopharmaceutical company, has reportedly announced expanded results from the earlier reported short-term analysis of ROCKstar (KD025-213), the company’s ongoing crucial trial of KD025 in chronic GVHD (graft-v....
VBL Therapeutics, a renowned Israeli biopharmaceutical company, reportedly announced the initiation of phase 2 clinical study of VB-111 combined with immune checkpoint inhibitor, nivolumab (Opdivo®). This study would be conducted to fin....
Advaxis, Inc., a clinical-stage biotechnology company developing and commercializing immunotherapy products, has reportedly announced positive outcomes from the monotherapy and combination arms of its in progress Phase 1/2 clinical trial st....
Matinas BioPharma, a renowned biopharmaceutical company, has reportedly announced that DSMB (Data Safety Monitoring Board) for the EnACT study has finished its planned review of initial tolerability and safety data from the Part 1 dose esca....
MB-106 has been developed for cancer in partnership with Fred Hutchinson Cancer Research Center Phase 1/2 clinical trial is assessing the maximum tolerable MB-106 dose Mustang Bio, Inc., a biopharma firm involved in the transla....
The U.S. FDA (Food and Drug Administration) has reportedly approved three drugs as an over-the-counter product; GlaxoSmithKline's Voltaren Arthritis Pain and Alcon’s two allergy-related drugs. As per sources, the agency has switch....
Bristol-Myers demonstrates five year follow up results from CheckMate-25 Phase 3 study for Opdivo in patients with formerly treated advanced or metastatic RCC As per the results, nearly 26 per cent of patients are alive from Opdi....
Pulse Biosciences, Inc., an innovative bioelectric medicine company committed to improving the lives of patients, has reportedly announced an update on its U.S. FDA ( Food and Drug Administration) submission for the CellFX System. Earlier, ....
Abeona Therapeutics Inc., a leading biopharmaceutical firm focusing on cell and gene therapy, has recently revealed that Abigail Wexner Research Institute’s (AWRI) researchers from Nationwide Children’s Hospital have shown encou....
Japanese multinational pharmaceutical company, Astellas Pharma Inc. and U.S-based Pfizer Inc. have reportedly announced results of final OS (overall survival) analysis from the Phase 3 PROSPER clinical trial, which assessed XTANDI® (enz....
